BTS150

- Presenation in 2019 RESI and BIO USA  in Philadelpia


Our lead asset BTS-150 is in the end of pre-clinical trials. The anticancer efficacy against human xenograft tumors in nude mice models was performed using our test materials for the pre-clinical study of human lung cancer.

BTS-150 leverages BIO3S’ proprietary technology as cancer metabolism drug that can only starve cancer cells and necrotize them by inhibiting lactate dehydrogenase A (LDHA) and hypoxia-inducible factor 1 alpha (HIF1a) to reduce tumor progression.  

If you need our pitchdeck, please e-mail to joseph@bio3s.com